156 related articles for article (PubMed ID: 20022911)
1. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.
Vermaat JS; van der Tweel I; Mehra N; Sleijfer S; Haanen JB; Roodhart JM; Engwegen JY; Korse CM; Langenberg MH; Kruit W; Groenewegen G; Giles RH; Schellens JH; Beijnen JH; Voest EE
Ann Oncol; 2010 Jul; 21(7):1472-1481. PubMed ID: 20022911
[TBL] [Abstract][Full Text] [Related]
2. Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.
Vermaat JS; Gerritse FL; van der Veldt AA; Roessingh WM; Niers TM; Oosting SF; Sleijfer S; Roodhart JM; Beijnen JH; Schellens JH; Gietema JA; Boven E; Richel DJ; Haanen JB; Voest EE
Eur Urol; 2012 Oct; 62(4):685-95. PubMed ID: 22285764
[TBL] [Abstract][Full Text] [Related]
3. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
4. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
Tamura K; Ando R; Takahara K; Ito T; Kanao K; Yasui T; Shiroki R; Miyake H
Urol Oncol; 2021 Jan; 39(1):78.e1-78.e8. PubMed ID: 32958444
[TBL] [Abstract][Full Text] [Related]
5. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer.
Wood SL; Rogers M; Cairns DA; Paul A; Thompson D; Vasudev NS; Selby PJ; Banks RE
Br J Cancer; 2010 Jun; 103(1):101-11. PubMed ID: 20531413
[TBL] [Abstract][Full Text] [Related]
6. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
7. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.
Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A
Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma.
Stenman M; Laurell A; Lindskog M
Med Oncol; 2014 Mar; 31(3):841. PubMed ID: 24477648
[TBL] [Abstract][Full Text] [Related]
10. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients.
Tolson J; Bogumil R; Brunst E; Beck H; Elsner R; Humeny A; Kratzin H; Deeg M; Kuczyk M; Mueller GA; Mueller CA; Flad T
Lab Invest; 2004 Jul; 84(7):845-56. PubMed ID: 15107802
[TBL] [Abstract][Full Text] [Related]
11. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice.
Kamba T; Yamasaki T; Teramukai S; Shibasaki N; Arakaki R; Sakamoto H; Matsui Y; Okubo K; Yoshimura K; Ogawa O
Int J Clin Oncol; 2014; 19(3):505-15. PubMed ID: 23813043
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
Kubackova K; Melichar B; Bortlicek Z; Pavlik T; Poprach A; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Prausova J; Buchler T;
Target Oncol; 2015 Dec; 10(4):557-63. PubMed ID: 25903462
[TBL] [Abstract][Full Text] [Related]
13. Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma.
Giridhar KV; Sosa CP; Hillman DW; Sanhueza C; Dalpiaz CL; Costello BA; Quevedo FJ; Pitot HC; Dronca RS; Ertz D; Cheville JC; Donkena KV; Kohli M
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099775
[TBL] [Abstract][Full Text] [Related]
14. Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.
Kwon WA; Cho IC; Yu A; Nam BH; Joung JY; Seo HK; Lee KH; Chung J
Ann Surg Oncol; 2013 Dec; 20(13):4397-404. PubMed ID: 24081805
[TBL] [Abstract][Full Text] [Related]
15. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
16. Baseline Edmonton Symptom Assessment System and survival in metastatic renal cell carcinoma.
Graham J; Gingerich J; Lambert P; Alamri A; Czaykowski P
Curr Oncol; 2018 Aug; 25(4):e319-e323. PubMed ID: 30111978
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment Lymphocyte to Monocyte Ratio is an Independent Prognostic Factor in Metastatic Clear Cell Renal Cell Carcinoma.
Gu L; Ma X; Xie Y; Li H; Wang L; Chen L; Zhao W; Zhang Y; Zhang X
Clin Genitourin Cancer; 2017 Jun; 15(3):e369-e377. PubMed ID: 28038932
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma: Model development and external validation with Memorial Sloan Kettering Cancer Center model and the international metastatic renal cell carcinoma database consortium model.
Shin D; Jeong CW; Song C; Kang M; Seo SI; Kim JK; Lee H; Chung J; Hong SH; Hwang EC; Kwak C; Park JY
Medicine (Baltimore); 2021 Aug; 100(31):e26826. PubMed ID: 34397846
[TBL] [Abstract][Full Text] [Related]
19. Differential expression and clinical significance of serum protein among patients with clear-cell renal cell carcinoma.
Nuerrula Y; Rexiati M; Liu Q; Wang YJ
Cancer Biomark; 2015; 15(4):485-91. PubMed ID: 26406868
[TBL] [Abstract][Full Text] [Related]
20. Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.
de Bruijn RE; Nijkamp J; Noe A; Horenblas S; Haanen JB; Prevoo W; Bex A
Urol Oncol; 2016 Jun; 34(6):258.e7-258.e13. PubMed ID: 26822077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
